<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00456092</url>
  </required_header>
  <id_info>
    <org_study_id>CC-10004-PSA-001</org_study_id>
    <nct_id>NCT00456092</nct_id>
  </id_info>
  <brief_title>Phase II Study With CC-10004 in Psoriatic Arthritis</brief_title>
  <official_title>A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of CC-10004 in Subjects With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to look at the preliminary efficacy and safety of CC-10004 vs placebo in
      patients with active psoriatic arthritis. The pharmacokinetics of the compound in patients
      will also be explored, and biopsies will be taken of the skin and the knee synovium to look
      at the activity of the drug in the relevant tissues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to look at the preliminary efficacy and safety of CC-10004 vs placebo in
      patients with active psoriatic arthritis. Participants must have a minimum of 6 months
      history of psoriatic arthritis to qualify. Prior to the implementation of Amendment 1/UK3 the
      study was in 3 phases - pre-randomisation up to 35 days, up to 84 days treatment and a 28 day
      follow up. After the implementation of Amendment 1/UK3, the study is in 4 phases -
      pre-randomization up to 35 days, up to 84 days treatment in the placebo controlled treatment
      phase, up to 84 days treatment in the active treatment extension phase and a 28 day follow
      up. Treatment groups are 40 milligrams (mg) once daily (od), 20 mg twice daily (bd) or
      placebo. To ameliorate the dose dependent adverse events of CC-10004 (headache and
      gastro-intestinal (GI) disturbances) there will be dose titration of 10mg od (or placebo) for
      days 1 to 3 followed by 20 mg od (or placebo) days 4 to 7 in the first week of dosing.
      Patients changing from placebo to active treatment on entry to the extension phase will
      undergo dose titration of 10mg od for days 85 to 87 followed by 20mg od days 88 to 91.
      Assessments take place after week 1 and then every 2 weeks during the treatment phase. Plasma
      pharmacokinetics of CC-10004 will be evaluated in a subset of patients from each active
      treatment group during the placebo controlled treatment phase. Normal and psoriatic skin
      biopsies and/or synovial biopsies will be taken for evaluation of histopathology and
      biomarkers from subsets of patients in each treatment group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology Criteria for 20% improvement (ACR 20)</measure>
    <time_frame>Up to Day 169</time_frame>
    <description>Proportion of participants who achieve ACR 20</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with AEs</measure>
    <time_frame>Up to Day 169</time_frame>
    <description>Type, frequency, severity and relationship of adverse events to CC-10004</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants prematurely discontinuing due to AEs</measure>
    <time_frame>Up to Day 169</time_frame>
    <description>Number of participants prematurely discontinuing due to any adverse event during all phases of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of clinically significant changes AEs associated events related to a physical examination, vital signs, electrocardiogram (ECG) and/or laboratory findings</measure>
    <time_frame>Up to Day 169</time_frame>
    <description>Frequency of clinically significant changes AEs associated with a physical examination, vital signs, electrocardiogram (ECG) and/or laboratory findings during all treatment phases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency that a participant is unable to withstand dose titration.</measure>
    <time_frame>Up to Day 169</time_frame>
    <description>Frequency of participants unable to withstand dose titration during the during all treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The frequency of participants who discontinue due to inability to withstand study medication adverse effects</measure>
    <time_frame>Up to Day 85&amp; 169</time_frame>
    <description>Frequency of participants who discontinue due to inability to withstand study medication adverse effects during any treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriatic Arthritis Response Criteria (PsARC)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Proportion of participants who meet PsARC, from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Criteria for 50% improvement (ACR 50)</measure>
    <time_frame>Up to Day 85&amp; 169</time_frame>
    <description>Proportion of participants who achieve ACR 50, from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Criteria for 70% improvement (ACR 70)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Proportion of participants who achieve ACR 70 from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Criteria for 90% improvement (ACR 90)</measure>
    <time_frame>Up to Day 85 &amp;169</time_frame>
    <description>Proportion of participants who achieve ACR 90 from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score (DAS28)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Proportion of participants who achieve a 'good' or 'moderate' response according to DAS28 from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (DAS28)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Proportion of participants whose disease severity is 'mild' or 'in remission' according to DAS from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who withdraw prematurely due to lack of efficacy</measure>
    <time_frame>Up to Day 169</time_frame>
    <description>Proportion of participants who withdraw prematurely due to lack of efficacy from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who dose reduce</measure>
    <time_frame>Up to Day 169</time_frame>
    <description>Proportion of participants who dose reduce from baseline through the end of the extension phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Criteria response</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Maximal ACR response from baseline to the end of the extension phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Criteria for 20% improvement (ACR 20)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Time to achieve ACR 20 from baseline to the end of the extension phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Criteria for 50% improvement (ACR 50)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Time to achieve ACR 50 from baseline to the end of the extension phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Criteria for 70% improvement (ACR 70)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Time to achieve ACR 70 from baseline to the end of the extension phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology Criteria for 90% improvement (ACR 90)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Time to achieve ACR 90 from baseline to the end of the extension phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dactylitis Score</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Change in dactylitis score from baseline through Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enthesitis incidence proportion</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Proportion of participants with and without enthesitis from baseline through Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Relapse of Psoriatic arthritis</measure>
    <time_frame>Up to Day 169</time_frame>
    <description>Time to relapse of psoriatic arthritis in participants who achieved at least an ACR 20 response from baseline through Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who relapsed during observational follow up</measure>
    <time_frame>Up to Day 169</time_frame>
    <description>Proportion of participants who relapsed during observational follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form 36 Version 2 (SF-36)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Change in SF-36 Score, from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Change in DLQI from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Health Assessment Questionnaire Disability Index (HAQ-DI)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Change in HAQ-DI from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Functional Assessment of Chronic Illness Therapy for Fatigue (FACIT-F)</measure>
    <time_frame>Up to Day 85 &amp; 169</time_frame>
    <description>Change in SF-36 from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in T cell, B cell and NK cells in peripheral blood harmacodynamic (PD)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Change in T cell, B cell and NK cells in peripheral blood at Day 85, and early termination from Treatment Phase visit from baseline to Day 169</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in synovitis (synovium thickness and vascularity) and inflammatory markers in synovial tissue</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Change in synovitis (synovium thickness and vascularity) and inflammatory markers in synovial tissue from baseline to Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in epidermal thickness and inflammatory markers in psoriatic skin</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Change in epidermal thickness and inflammatory markers in psoriatic skin from baseline to Day 85</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time 0 to 8 hours from dosing (AUC</measure>
    <time_frame>Day 71</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to 8 hours from dosing (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration</measure>
    <time_frame>Day 71</time_frame>
    <description>Peak plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration</measure>
    <time_frame>Day 71</time_frame>
    <description>Time to maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of PK to PD and clinical outcomes)</measure>
    <time_frame>Day 71</time_frame>
    <description>Relationship of PK to PD and clinical outcomes</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Apremilast 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg CC-10004 orally twice a day (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apremilast 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg CC-10004 orally every day (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo identical to CC-10004 orally BID or QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-10004</intervention_name>
    <description>20mg CC-10004 twice a day orally following dose titration)</description>
    <arm_group_label>Apremilast 20 mg</arm_group_label>
    <other_name>Apremilast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-10004</intervention_name>
    <description>40 mg CC-10004 QD following dose titration</description>
    <arm_group_label>Apremilast 40 mg</arm_group_label>
    <other_name>Apremilast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>: Placebo identical to CC-10004 orally BID or QD following dose titration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of psoriatic arthritis (Moll and Wright Criteria), including symmetrical or
             asymmetrical peripheral joint involvement for at least 6 months

          -  Active psoriatic arthritis at the time of screening and baseline as defined by:

             3 or more swollen joints AND 3 or more tender joints

          -  Negative rheumatoid factor (RF)

          -  If using methotrexate, be on methotrexate for at least 168 days (24 weeks) and be on a
             stable dose for at least 56 days prior to screening and throughout the study

          -  If using oral corticosteroids, be on a stable dose of prednisone ≤ 10 mg/day or
             equivalent for at least 28 days prior to screening and throughout the study

          -  If using nonsteroidal anti-inflammatory drug (NSAID) therapy, be on a stable dose for
             at least 14 days prior to screening and throughout the study

          -  Must meet the following laboratory criteria:

               -  Hemoglobin ≥ 9 g/dL

               -  Hematocrit ≥ 27%

               -  White blood cell (WBC) count ≥ 3000 /μL (≥ 3.0 X 109/L) and &lt; 20,000/μL (&lt; 20 X
                  10^9/L)

               -  Neutrophils ≥ 1500 /μL (≥ 1.5 X 10^9/L)

               -  Platelets ≥ 100,000 /μL (≥ 100 X 10^9/L)

               -  Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)

               -  Total bilirubin ≤ 2.0 mg/dL

               -  Aspartate transaminase (AST [serum glutamic oxaloacetic transaminase, SGOT]) and
                  alanine transaminase (ALT [serum glutamate pyruvic transaminase, SGPT]) ≤ 1.5x
                  upper limit of normal (ULN)

          -  Females of childbearing potential (FCBP) must have a negative urine pregnancy test at
             screening (Visit 1). In addition, sexually active FCBP must agree to use TWO adequate
             forms of contraception while on study medication. A FCBP must agree to have pregnancy
             tests every 28 days while on study medication

          -  Males (including those who have had a vasectomy) must agree to use barrier
             contraception (latex condoms) when engaging in reproductive sexual activity with FCBP
             while on study medication and for at least 84 days after taking the last dose of study
             medication

        Exclusion Criteria:

        History of any clinically significant cardiac, endocrinologic, pulmonary, neurologic,
        psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study

          -  Pregnant or lactating female

          -  History of active Mycobacterium tuberculosis infection (any subspecies) within 3 years
             prior to the screening visit. Infections that occurred &gt; 3 years prior to entry must
             have been effectively treated.

          -  History of incompletely treated latent Mycobacterium tuberculosis infection (as
             indicated by a positive Purified Protein Derivative [PPD] skin test or in vitro test
             [T SPOT®.TB, QuantiFERON Gold®])

          -  Clinically significant abnormality on the chest x-ray (CXR) at screening

          -  Current erythrodermic, guttate, or pustular forms of psoriasis

          -  History of infected joint prosthesis within the past 5 years

          -  Systemic therapy for psoriasis and/or psoriatic arthritis (except for methotrexate, ≤
             10 mg/day prednisone or equivalent, and NSAIDs) including, but not limited to,
             sulfasalazine, leflunomide, chloroquine, hydroxychloroquine, gold compounds,
             parenteral corticosteroids (including intra-articular), penicillamine, cyclosporine,
             oral retinoids, mycophenolate mofetil, thioguanine, hydroxyurea, sirolimus,
             tacrolimus, azathioprine, and fumaric acid esters within 28 days of randomization and
             throughout the study

          -  Topical therapy for the treatment of psoriasis including, but not limited to topical
             steroids, topical vitamin A or D analog preparations, tacrolimus, pimecrolimus, or
             anthralin within 14 days of randomization (Note: Topical background therapy for
             treatment of psoriasis is allowed, except within 24 hours of a study visit, as
             follows: mild or moderate potency corticosteroids for treatment of the palms, face,
             scalp, axillae, plantar surfaces, and groin in accordance with the manufacturer's
             suggested usage. Nonmedicated emollients [eg, Eucerin®] and tar shampoo are also
             allowed.)

          -  Phototherapy (ultraviolet light A [UVA], narrow-band ultraviolet light B [NB-UVB],
             psoralens and long-wave ultraviolet radiation [PUVA]) within 28 days prior to
             randomization

          -  Etanercept use within 56 days prior to randomization

          -  Adalimumab, efalizumab, or infliximab use within 84 days prior to randomization

          -  Alefacept use within 168 days (24 weeks) prior to randomization

          -  Use of intra-articular corticosteroids within 28 days prior to randomization

          -  Use of any investigational medication within 28 days prior to randomization or 5
             half-lives if known (whichever is longer)

          -  Any clinically significant abnormality on 12-lead ECG at screening

          -  High-risk factor(s) for, or a history of, human immunodeficiency virus (HIV),
             hepatitis B, or hepatitis C virus infection

          -  History of malignancy within previous 5 years (except for treated basal-cell skin
             carcinoma(s) and/or fewer than 3 treated squamous-cell skin carcinomas)

          -  Evidence of skin conditions at the time of screening visit that would interfere with
             evaluations of the effect of study medication on psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Keystone</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, Rebecca MacDonald Centre for Arthritis and Auto-immune disease, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carter Thorne</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arthritis Program Research Group, Ontario</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt de Vlam</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P Geusens</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Hasselt, Diepenbiek</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Bentin</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann Dept Rheumatology, Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rik Joos</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jan Palfijn Ziekenhuis, Merksem</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Georg Schett</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friedrich-Alexander-University, Erlangen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerd Burmester</last_name>
    <role>Principal Investigator</role>
    <affiliation>Free University of Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harald Burkhardt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsklinikum Frankfurt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holm Haentzschel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaet Leipzig</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Lorenz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaet Heidelberg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Rubbert</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsklinik Koeln</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Simon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaetsklinikum Leipzig, Dept of Dermatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jurgen Wollenhaupt</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Eilbek, Hamburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piet van Riel</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T W Huizinga</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H K Ronday</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hagaziekenhuis, Den Haag</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Emery</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chapel Allerton Hospital, Leeds</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert G Cooper</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hope Hospital, Salford, Manchester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Ostor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Addenbrooke's Hospital, Cambridge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Kirkham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guys and St Thomas' Hospital, London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Packham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Haywood Hospital, Stoke on Trent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Walker</last_name>
    <role>Principal Investigator</role>
    <affiliation>Freeman Hospital, Newcastle</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Zhu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universiteit Hasselt</name>
      <address>
        <city>Diepenbeek</city>
        <zip>3590</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jan Palfijn Ziekenhuis</name>
      <address>
        <city>Merksem</city>
        <zip>2170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Research Centre of Canada</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8P4Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus Clinical Research</name>
      <address>
        <city>St Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Burlington Rheumatology and Osteoporosis Clinic</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7R 4B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAC Research Inc.</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 2B6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K-W Musculoskeletal Research Inc.</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 5N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Rheumatology</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Program Research Group Inc</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Associates</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Prognosis Studies in the Rheumatic Diseases University Health Network, Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Probity Medical</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research and Arthritis Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Island Rheumatology Research Associates</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saskatoon Osteoporosis Center</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 0H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio Franz von Prümmer Klinik</name>
      <address>
        <city>Bad Brückenau</city>
        <zip>97769</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Free University of Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <zip>44652</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Koeln</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Munster</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Alexander University, Erlangen</name>
      <address>
        <city>Nuremberg</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hagaziekenhuis</name>
      <address>
        <city>Den Haag</city>
        <zip>2454 CH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <zip>2300</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Hospital</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haywood Hospital</name>
      <address>
        <city>Stoke on Trent</city>
        <state>Staffs</state>
        <zip>ST6 7AG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Allerton Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2007</study_first_submitted>
  <study_first_submitted_qc>April 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2007</study_first_posted>
  <disposition_first_submitted>March 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>July 26, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 2, 2013</disposition_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriatic arthritis</keyword>
  <keyword>ACR</keyword>
  <keyword>PASI</keyword>
  <keyword>DAS</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

